Newsroom 2008

2008 Releases

13/10/2008
CSL Receives FTC Request for Additional Information
CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics More.

02/09/2008
CSL Appoints New Director
CSL today announced that Mr David Anstice has been appointed a Director of the Company effective 2 September 2008. More.

13/08/2008
Full Year Results for 2008
CSL Limited today announced a profit after tax of $702 million for the twelve months ended 30 June 2008, up 30% when compared to the twelve months ended 30 June 2007. On a constant currency basis profit grew 45%. More.

17/06/2008
CSL Receives TGA Approval to Register Panvax®, Avian Flu Vaccine
CSL Limited announced today that it has received approval from the Australian Therapeutic Goods Administration (TGA) to register Panvax®, CSL’s avian influenza vaccine. Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus. More.

20/02/2008
CSL Half Year Results Announcement for 2007/08
CSL Limited today announced a profit after tax of $349 million for the six months ended 31 December 2007, up 36% when compared to the six months ended 31 December 2006. This included an adverse foreign currency impact of $28m, when compared with the prior comparable period (PCP). More.

10/02/2008
CSL Limited Warns Shareholders of Unsolicited Share Offers
CSL Limited has become aware of unsolicited offers to shareholders to purchase their shares for a price which significantly undervalues their holding. CSL has advised shareholders, on receipt of such an offer, that they check it carefully. More.

© 2016 CSL Limited